Galderma’ Azzalure (botulinum toxin Type A), manufactured by Ipsen, has received marketing authorization in from the regulatory authorities in Germany. It is meant for the temporary improvement in the appearance of moderate-to-severe glabellar lines seen at the frown.
The approval was based on several clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure.
Marc Wannhoff, General Manager of Galderma, said: “Azzalure’s marketing authorisation is an important event for patients who need corrective and aesthetic procedures. Azzalure is the latest product in our expanding range of dermatology treatments and emphasizes our commitment to the future of dermatology.”
Azzalure will be commercially available in Germany by the third quarter of 2009.